Iron oxide and gold bimetallic radiosensitizers for synchronous tumor chemoradiation therapy in 4T1 breast cancer murine model-Reference-Cited by-同舟云学术

Iron oxide and gold bimetallic radiosensitizers for synchronous tumor chemoradiation therapy in 4T1 breast cancer murine model

Published:2021 Issue:22 Volume:9 Page:4510-4522
ISSN:2050-750X
Container-title:Journal of Materials Chemistry B
language:en
Short-container-title:J. Mater. Chem. B

Author:

Nosrati Hamed¹²³⁴⁵^ORCID,Baghdadchi Yasamin¹²³⁴,Abbasi Reza⁶³⁴,Barsbay Murat⁷⁸⁹¹⁰^ORCID,Ghaffarlou Mohammadreza⁷⁸⁹¹⁰,Abhari Fatemeh¹²³⁴,Mohammadi Ali¹²³⁴,Kavetskyy Taras⁵¹¹¹²¹³¹⁴,Bochani Shayesteh¹²³⁴,Rezaeejam Hamed¹⁵¹⁶³⁴,Davaran Soodabeh¹⁷¹⁸¹⁹⁴,Danafar Hossein¹²³⁴⁵^ORCID

Affiliation:

1. Cancer Gene Therapy Research Center

2. Zanjan University of Medical Sciences

3. Zanjan

4. Iran

5. Joint Ukraine-Azerbaijan International Research and Education Center of Nanobiotechnology and Functional Nanosystems

6. Department of Physics, Faculty of Science, University of Zanjan

7. Hacettepe University

8. Department of Chemistry, Beytepe

9. Ankara 06800

10. Turkey

11. Baku

12. Azerbaijan

13. Department of Surface Engineering, The John Paul II Catholic University of Lublin

14. 20-950 Lublin

15. Department of Radiology

16. School of Paramedical Sciences, Zanjan University of Medical Sciences

17. Drug Applied Research Center

18. Tabriz University of Medical Sciences

19. Tabriz

Abstract

The development of highly integrated multifunctional nanomaterials with a superadditive therapeutic effect and good safety is an urgent but challenging task in cancer therapy research.

Funder

Zanjan University of Medical Sciences

Türkiye Bilimsel ve Teknolojik Araştirma Kurumu

Publisher

Royal Society of Chemistry (RSC)

Subject

General Materials Science,Biomedical Engineering,General Chemistry,General Medicine

Link

http://pubs.rsc.org/en/content/articlepdf/2021/TB/D0TB02561E

Reference46 articles.

1. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

2. Emerging Strategies of Nanomaterial‐Mediated Tumor Radiosensitization